Adlai Nortye Group Ltd. ADR (ANL)
NASDAQ: ANLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ANL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $550.60M
- EPS (TTM)
- -$0.66
- Dividend yield
- None
- 52-week range
- 0.879 – 17.25
- Day range
- 8.36 – 9.11
- Volume / Avg
- 380.64K / 244.74K
- Beta
- —
- Shares outstanding
- 58.73M
52-week range
ANL stock today
Adlai Nortye Group (ANL) closed at $8.55 on Nov 20, down 5.63% (-$0.51), versus the S&P 500's 3.70% decline. Shares are 50.4% below their 52-week high of $17.25, set on Apr 21, 2026 and 872.7% above the 52-week low of $0.879, in the middle of the past year's range. ANL is up 502.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 533.3%.
Adlai Nortye Group has posted a net loss over the last twelve months (EPS of -$0.66), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Adlai Nortye Group
Company profileAdlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Yang Lu EMBA
- Headquarters
- Singapore
- Employees
- 109
- IPO year
- 2023
- Website
- adlainortye.com
Financial highlights
Full financialsAdlai Nortye Group reported a net loss of $51.9 million, compared with a loss of $109.2 million a year earlier. Diluted earnings per share came in at -$0.54.
| Fiscal year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Revenue | — | $5.00M | — | $45.73M |
| Growth | — | — | — | — |
| Net income | $-51.87M | $-109.23M | $-58.79M | $-56.68M |
| EPS (diluted) | $-0.54 | $-2.52 | $-2.31 | $-2.23 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$29.50+245.03%
- Strong buy 0
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
ANL news
All ANL news- Weekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report DataNasdaqABBV, ANL, ARWR, AZN
- Adlai Nortye Partners With Lilly And Merck KGaA To Evaluate AN4035 Combination In Solid TumorsNasdaqANL, LLY
- Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and CetuximabGlobeNewswire
- Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?NasdaqANL, TMO
Adlai Nortye Group peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ACRSAclaris Therapeutics Inc. | 3.44 | -1.71% | $545.63M | vs ANL |
| AVBPArriVent BioPharma Inc. | 10.52 | -6.57% | $544.13M | vs ANL |
| CBIOCrescent Biopharma Inc. | 13.00 | +0.70% | $543.21M | vs ANL |
| BCAXBicara Therapeutics Inc. | 8.44 | -7.46% | $560.31M | vs ANL |
| GERNGeron Corporation | 0.8707 | -4.63% | $560.94M | vs ANL |
| CLYMClimb Bio Inc. | 9.19 | -0.97% | $539.80M | vs ANL |
| DSGNDesign Therapeutics Inc. | 9.02 | -3.22% | $577.61M | vs ANL |
| ZVRAZevra Therapeutics Inc. | 8.76 | -3.42% | $521.26M | vs ANL |
Indexes, lists and sector
Adlai Nortye Group stock FAQ
What is Adlai Nortye Group's stock price today?
ANL last traded at $8.55 as of Nov 20, 4:00 PM EST, down 5.63% on the day. Prices are delayed at least 15 minutes.
Who is Adlai Nortye Group's CEO?
Mr. Yang Lu EMBA is the chief executive officer of Adlai Nortye Group Ltd. ADR, which has about 109 employees.
What is the ANL 52-week high?
The 52-week high for ANL is $17.25 and the 52-week low is $0.879. The stock is currently 50.4% below its high.